Systemic sclerosis & Raynaud's
Multiomics landscape of systemic sclerosis: from autoantibody-positivity to established disease
Authors' conclusion
Molecular abnormalities associated with SSc are detectable before overt clinical disease.
Study context
- Population
- Healthy controls and individuals across the systemic sclerosis (SSc) spectrum from SSc-specific autoantibody-positive (SSAP) through very early diagnosis of SSc (VEDOSS) to established limited and diffuse SSc
- Comparison
- Healthy controls vs SSAP vs VEDOSS vs limited and diffuse SSc
- Outcome
- Molecular alterations across the SSc spectrum
Methodological detailsmultiomics, PBMC transcriptomics, plasma proteomics, Connectivity Map analysis
- Multiomics
- PBMC transcriptomics
- Plasma proteomics
- Connectivity Map analysis
Main finding
As reported in the abstract
- Continuous molecular gradient from health to established SSc, with SSAP and VEDOSS in intermediate molecular states
- Immune dysregulation, particularly innate immune activation and type I interferon signalling, detectable at the SSAP stage, with higher activity across the ordered clinical groups
- Plasma proteomics identified circulating protein markers related to vascular injury and extracellular matrix remodelling across the clinical groups
- Connectivity Map (CMap) prioritised JAKi and phosphodiesterase inhibitors as hypothesis-generating perturbagens linked to early disease-associated programmes
Original publication
Multiomics landscape of systemic sclerosis: from autoantibody-positivity to established disease. Ann Rheum Dis. Published 22 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →